10/17/2007

Merck & Co. has licensed Protiva Biotherapeutics' Stable Nucleic Acid-Lipid Particles technology, which involves RNA interference in the research and development of nucleic acid-based drugs. Protiva also said it agreed to end all litigation against Merck unit Sirna Therapeutics in connection with the licensing agreement.

Related Summaries